10th International AIDS Society Conference on HIV Science

Slides:



Advertisements
Similar presentations
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
Advertisements

PMTCT FAILURE: THE ROLE OF MATERNAL AND FACILITY –RELATED FACTORS ICASA Presentation 8 th to 12 th Dec 2013 Onono Maricianah 1, Elizabeth A. Bukusi 1,
Safety of efavirenz in first- trimester of pregnancy Systematic review and meta-analysis of outcomes from observational cohorts Nathan Ford, MSF/UCT Lynne.
What Is Pharmacovigilance and Why Is It Important? Margarett Davis, MD, MPH Centers for Disease Control and Prevention Atlanta, Georgia ART in Pregnancy,
Vannappagari et al, 20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia. Poster #5647 Prenatal Exposure to Zidovudine and Risk for.
Andrews 3/27/00 SP1 Pregnancy Follow-up Studies Lessons from Glaxo Wellcome Experience.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
Introducing HealthStats Eleanor Howell, MS Manager, Data Dissemination Unit State Center for Health Statistics February 2, 2012.
Increasing Folic Acid Awareness and Knowledge of Future Health Care Providers to Reduce the Incidence of Neural Tube Birth Defects Increasing Folic Acid.
Training course on Introducing pharmacovigilance into HIV/AIDS programmes Pretoria, South Africa, September 1-10,2004.
44 th Annual Meeting of the European Association for the Study of the Liver April 22 – 26, 2009 Copenhagen, Denmark Oral # Hepatitis B Virus Drugs in Pregnancy:
Pregnancy Registries’ Contribution to Informed Clinical Practice Third Annual International Conference for Individualized Pharmacotherapy in Pregnancy.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Public Health Birth Defects Surveillance
INTRODUCTION Evaluation of Outcomes in Patients Starting Antiretroviral Therapy During Hospitalization Leigh E. Efird, PharmD 1, Manish Patel, PharmD 1,
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.
Hit Hard, Hit Early: When to Treat and With What? Brian G. Gazzard, MD, Moderator Julio Montaner, MD Calvin J. Cohen, MD, MS.
Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.
The Role of Residential Segregation in Disparity Research: A Case Example of ADHD Diagnosis and Treatment Dinci Pennap, MPH, 1 Mehmet Burcu, MS, 1 Daniel.
Gateway to the Future: Improving the National Vital Statistics System St. Louis, MO June 6 th – June 10 th, 2010 Abortion Surveillance in the United States:
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Factors associated with maternal smoking during early pregnancy: relationship to low-birth-weight infants and maternal attitude toward their pregnancy.
 Reduction in Perinatal Transmission of the HIV in Barbados after intervention with anti-retroviral therapy. M. Anne St John Consultant Paediatrician,
Understanding the Rationale of the 2015 WHO Guidelines on PrEP IAS Satellite Session Heather Watts M.D. Office of the Global AIDS Coordinator July 18,
Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects Björn Pasternak; Anders Hviid R3 Jungwook.
Global Antiviral Drugs Market Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022 Phone No.: +1 (214) id:
Global Orphan Drug Market 2017 Analysis, Segmentation, Competitors Analysis, Trends and Forecast by 2022 Phone No.: +1 (214) id:
Zika in Texas The State Perspective
Trends in maternal deaths in HIV-infected women, on a background of changing HIV management guidelines in South Africa: 1997 to ,2,3CN Mnyani, 1EJ.
Optimizing Antiretorviral Therapy for Long-Term HIV Care
OVERVIEW OF PREVENTING MOTHER TO CHILD TRANSMISSION OF HIV
Module 4 (e) Pregnancy and Breast Feeding
Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects William W. Thompson, PhD Presented at the.
Participants 18year old+
Infant clinical considerations
Patient Registries and Health Outcomes in Diabetes: A Retrospective Study Nipa Shah, MD1; Fern Webb, PhD1; Liane Hannah, BSH1; Carmen Smotherman, MS2;
DEPARTMENT OF PAEDIATRICS, THE QUEEN ELIZABETH HOSPITAL,
Maternal Toxicity Management
Keerti Singh, C Greaves, L Mohammed, A Kumar.
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
What’s New in the Perinatal Guidelines
P r e g n a n c y , E p i l e p s y a n d A n t i e p i l e p t i c d r u g s : N e e d F o r T e r a t o v i g i l a n c e Dwajani S, Errol.
Chapter 4: Risk Reduction
Prof. Elaine Abrams September 13th 2018 ICAP at Columbia University
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
Session - Safety of DTG in Pregnancy: Late Breaking Findings, Interpretations, Implications July Overview on Safety of HIV Treatment in.
New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs)  HIV positive.
The Brazilian Experience
Sarah Siddiqui, MD, MPH University of Texas Medical Branch
What’s New in WHO Treatment Guidelines July What We Know About Safety Signals with DTG Use in Pregnancy Lynne M. Mofenson MD Senior HIV Technical.
Country Experiences monitoring new ARVs: Introductory Remarks
Botswana Moving Forward with DTG
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Prevention of mother to child transmission and early infant diagnosis in Malawi: Accomplishments of a mature Option B+ program in a resource-limited setting.
17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study David B. Nelson, MD; Donald D. McIntire,
Adele Schwartz Benzaken
Why Dolutegravir? Daniel R. Kuritzkes, M.D.
Reduction in Infant Cardiac Deaths in US States Implementing Policies to Screen Newborns for Critical Congenital Heart Disease Matthew Oster, MD, MPH Washington,
SCHS and Health Statistics
Christine Halleux, MD, PhD
Forecasting for ARVs medicines
ART Options and Treatment Decisions for Women of Reproductive Potential
TRANSITION TO TLD – ZIMBABWE REPORT
Joseph J. Eron, Jr, MD Professor of Medicine
Figure 1. Rate of PDR in infants according to ARV exposure
Dolutegravir in PEPFAR
10th International AIDS Society Conference on HIV Science
Antiretrovirals for prevention in women of childbearing age: issues to consider Landon Myer.
Presentation transcript:

10th International AIDS Society Conference on HIV Science Periconceptional Antiretroviral Exposure and Central Nervous System and Neural Tube Defects – Data from the Antiretroviral Pregnancy Registry Open spinal bifida (Copp & Greene, 2016, Encyclopedia of Life Sciences, John Wiley) LM Mofenson, V Vannappagari, AE Scheuerle, B Baugh, KP Beckerman, H Betman, N Chakhtoura, K Dominguez, A Pikis, NS Santanello, WR Short, CT Thorne, H Tilson, V Vinas, DH Watts, JD Albano on behalf of the APR Steering Committee 10th International AIDS Society Conference on HIV Science Mexico City, July 23 2019

Disclosures The APR is a collaborative project jointly funded by the following manufacturers: The views are those of the authors and do not reflect the opinions of the U.S. Department of State or the U.S. government AbbVie Accord Healthcare Alvogen Amneal Pharmaceuticals Apotex Aurobindo Pharma Boehringer Ingelheim Pharmaceuticals Bristol-Myers Squibb Company Celltrion Cipla F. Hoffman La-Roche Gilead Sciences Hetero Labs Hikma Pharmaeuticals USA Janssen Scientific Affairs Lannett Company Lupin Pharmaceutical Macleods Pharmaceuticals Merck & Company Mylan Laboratories Novartis Pharmaceuticals Prinston Pharmaceutical Qilu Pharmaceutical Sandoz Inc. SigmaPharm Laboratories Strides Shasun Teva Pharmaceuticals ViiV Healthcare

Introduction In May 2018, a potential signal of an increase in neural tube defects (NTD) with periconception dolutegravir (DTG) exposure was reported from the Tsepamo birth surveillance study in Botswana. There are limited data on birth defect outcome with periconception exposure outside the Tsepamo Study. We evaluated the prevalence of central nervous system (CNS) defect, NTDs and encephalocele (which is considered separately in the registry as it may occur slightly after neural tube closure) in the Antiretroviral Pregnancy Registry by drug class and specified individual drugs. Data are updated through January 31 2019 (and differ from abstract).

Birth Defect Surveillance: Antiretroviral Pregnancy Registry Since 1989, the Antiretroviral Pregnancy Registry has collected prospective, voluntary, anonymized reports of women on ART during pregnancy, capturing data after birth on birth outcomes. Provides an estimate of risk for major birth defects compared to general population, to give an early warning of potential teratogenicity. Currently international registry including 160 antiretroviral drugs – 57 brand, 103 generic drugs.

Ability to Rule-Out An Increase in Birth Defects With Drug Exposure is Related to Defect Prevalence and Number of Observed Exposures 200 exposures can rule out a 2-fold ↑ in overall birth defects (prevalence 3%) Watts DH. Curr HIV/AIDS Rep 2007;4:135-140 RR 2.0 Overall defect prevalence 3%

Ability to Rule-Out An Increase in Birth Defects With Drug Exposure is Related to Defect Prevalence and Number of Observed Exposures However, to rule-out a 3-fold increase in a rare event like NTD (prevalence 0.1%), need ~ 2,000 preconception exposures Neural tube defect prevalence 0.1% Watts DH. Curr HIV/AIDS Rep 2007;4:135-140 RR 3.0 Overall defects prevalence 3% RR 2.0

Reported during pregnancy before delivery, follow-up for outcome Antiretroviral Pregnancy Registry Analysis Prospective Retrospective Secondary Review for Clusters and Patterns Clinical Studies Reported during pregnancy before delivery, follow-up for outcome Timing, Dosage, Type of Antiretroviral Drug Use, Concomitant Exposures, and Pregnancy Outcome/Birth Defect at Time of Delivery Reported after birth, no denominator APR Primary Analysis number of defects^ number of live births Compared to: MACDP* 3/100 live births TBDR* 4/100 live births 1st trimester vs. 2nd & 3rd trimester Prevalence = Secondary Analyses ^ defects counted among all outcomes >20 wks gestation including stillbirth, induced abortion & live births * MACDP = Metropolitan Atlanta Congenital Defects Program; TBDR = Texas Birth Defects Registry

Methods Primary Analysis (Prospective) Clinicians register pregnant women with prenatal ARV exposures before pregnancy outcome is known, report data on exposure throughout pregnancy, and provide birth outcome data. Registration is voluntary & confidential; patient data is anonymized. Birth defects are reviewed by a dysmorphologist, coded according to modified Metropolitan Atlanta Congenital Defects Program (MACDP) criteria, and classified by organ system. Analysis includes birth defects, defined as ≥1 major birth defect or ≥2 minor defects.

Methods Data on prospectively enrolled pregnancies through January 2019 with birth outcome are summarized: Overall, by drug class and for selected specific drugs Earliest timing of exposure was assigned to each drug: Periconception – ARV exposure from 2 weeks before conception through ≤28 days after conception (6 weeks estimated gestational age) Later 1st trimester – Initial exposure started later in the 1st trimester (after 6 weeks estimated gestational age) 2nd/3rd trimester – Exposure started after the 1st trimester ended (> 12 weeks estimated gestational age) Birth defects in the central nervous system (CNS) include both NTDs & encephalocele (reported separately from NTD).

10,952 (54%) (8,546 [78%] periconception) Results – Primary Analysis Maternal Demographic & Clinical Characteristics of Pregnant Women, Primary Prospective Enrollments and Outcomes Through January 31 2019 Total pregnancies (N) 1st Trimester 2nd Trimester 3rd Trimester 20,372 10,952 (54%) (8,546 [78%] periconception) 7,018 (34%) 2,400 (12%) Maternal age at conception (years) Median Range (min-max) 29.0 13-55 CD4 T-cell count at time report N (%) ≥500 cells/µL 200-499 cells/µL <200 cells/µL 31.4% 39.1% 13.9%

Drug-Specific Overall Birth Defect Rates* Prevalence of Birth Defects (95% CI) with 1st Trimester Exposure: 1 January 1989 – 31 January 2019 *For drug to be included for comparison with population rates, must meet threshold of having ≥200 1st trimester exposed pregnancies Texas Birth Defects Registry (4.19%) Metropolitan Atlanta Congenital Defects Program (2.76%) No drug has 95% CI that significantly exceed population comparisons with exception of nelfinavir and ddI, which exceed MACDP but not TBDR and have no specific defect pattern 21 ARVs have ≥200 exposures 2.75% (CI 2.4-3.0%)

CNS and NTD in the Prospective APR by Drug Class and Selected ARVs Reports come from N America (75%), Europe (8%), Africa (7%), S America (6%) and Asia (4%). 20,727 pregnancy outcomes including 19,287 live births. There were 536 birth defect cases (2.8%), 51 CNS, including eight NTD (0.04%) and one encephalocele. Of the 8,546 with periconception exposure there were 241 birth defect cases (2.8%) and 23 CNS defects, including three NTD.

Prospective APR, Periconception: CNS and NTD by Drug Class Periconception ARV Live Births Any Defect CNS Defects Neural Tube Defect Encephalocele Any ART 8546 241 23 3 (0.03%)

Prospective APR, Periconception: CNS and NTD by Drug Class Periconception ARV Births Any Defect CNS Defects Neural Tube Defect Encephalocele Any ART 8546 241 23 3 (0.03%) Any NRTI/NtRTI ABC FTC 3TC TDF 8013 1027 2742 4129 3366 230 32 68 129 80 22 4 8 13 3 (0.04%) 1 (0.10%) 2 (0.07%) 1 (0.02%) 2 (0.06%)

Prospective APR, Periconception: CNS and NTD by Drug Class Periconception ARV Births Any Defect CNS Defects Neural Tube Defect Encephalocele Any ART 8546 241 23 3 (0.03%) Any NRTI/NtRTI ABC FTC 3TC TDF 8013 1027 2742 4129 3366 230 32 68 129 80 22 4 8 13 3 (0.04%) 1 (0.10%) 2 (0.07%) 1 (0.02%) 2 (0.06%) x Any PI ATV DRV LPV/r 3830 1067 436 949 112 25 16 9 3 1 5 1 (0.03%) 1 (0.09%)

Prospective APR, Periconception: CNS and NTD by Drug Class Periconception ARV Births Any Defect CNS Deects Neural Tube Defect Encephalocele Any ART 8546 241 23 3 (0.03%) Any NRTI/NtRTI ABC FTC 3TC TDF 8013 1027 2742 4129 3366 230 32 68 129 80 22 4 8 13 3 (0.04%) 1 (0.10%) 2 (0.07%) 1 (0.02%) 2 (0.06%) x Any PI ATV DRV LPV/r 3830 1067 436 949 112 25 16 9 3 1 5 1 (0.03%) 1 (0.09%) Any NNRTI EFV NVP RPV 2304 1037 943 329 57 28 2 1 (0.04%)

InSTI DTG EVG RAL 725 248 217 268 21 6 1 (0.14%) 1 (0.40%) Periconception ARV Births Any Defect CNS Defects Neural Tube Defect Encephalocele Any ART 8546 241 23 3 (0.03%) Any NRTI/NtRTI ABC FTC 3TC TDF 8013 1027 2742 4129 3366 230 32 68 129 80 22 4 8 13 3 (0.04%) 1 (0.10%) 2 (0.07%) 1 (0.02%) 2 (0.06%) x Any PI ATV DRV LPV/r 3830 1067 436 949 112 25 16 9 3 1 5 1 (0.03%) 1 (0.09%) Any NNRTI EFV NVP RPV 2304 1037 943 329 57 28 2 1 (0.04%) InSTI DTG EVG RAL 725 248 217 268 21 6 1 (0.14%) 1 (0.40%)

Prospective Antiretroviral Pregnancy Registry Periconception ARV Neural Tube Defect (NTD) Cases Details of Prospective NTD Case with Periconception Drug Exposure through January 2019 Defect Anencephaly Myelomeningocele Meningocele Drug exposure (timing) Abacavir (P) Dolutegravir (P) Lamivudine (P) Efavirenz (P) Emtricitabine (P) Tenofovir Disoproxil Fumarate (P) Lamivudine (T2) Nelfinavir (T2) Zidovudine (T2) Atazanavir (P) Emtricitabine (P) Ritonavir (P) Tenofovir Disoproxil Fumarate (P) Zidovudine (T3) Country of report US Outcome Stillbirth Livebirth Confounding factors Hispanic Fetal alcohol syndrome n/a P = periconception, T2 = second trimester, T3 = third trimester; US = United States

Conclusions The overall prevalence of NTD in 8,546 periconception ARV exposures was 0.03%. Most of the reports in the APR come from North America, where there is national food folic acid fortification which has been shown to reduce NTDs risk by 36%-68% in the general population (Wang Nutr 2016; Williams MMWR 2015; Ray Food Nutr Bull 2008 ) This frequency is consistent with the observed low NTD prevalence (0.01%-0.08%) in most developed countries due to reduced NTD occurrence from national food folic acid fortification and antenatal folic acid supplementation.

Conclusions In the updated APR data, there is one NTD with 248 periconception DTG exposures, giving a prevalence of 0.40% for DTG and 0.14% for InSTI class, but this is based on only one NTD in relatively small number of exposures. The number of pregnancies enrolled in the APR with InSTI periconception exposure are currently insufficient to rule out or confirm any potential association with NTD. Healthcare providers are encouraged to continue to report pregnancies with prospective antiretroviral exposures to the APR, especially those involving newer ARVs [www.APRegistry.com]

Conclusions ADVISORY COMMITTEE CONSENSUS In reviewing all reported defects from the prospective registry, informed by clinical studies and retrospective reports of antiretroviral exposure, the Registry finds no apparent increases in frequency of birth defects with first trimester exposures compared to exposures starting later in pregnancy and no pattern to suggest a common cause. While the Registry population exposed and monitored to date is not sufficient to detect an increase in the risk of relatively rare defects, these findings should provide some assurance when counseling patients. However, potential limitations of registries such as this should be recognized. The Registry is ongoing. Given the use of new therapies about which data are still insufficient, health care providers are strongly encouraged to report eligible patients to the Registry via the data forms available at www.APRegistry.com. The Antiretroviral Pregnancy Registry finds no apparent increases in frequency of defects with first trimester exposures compared to exposures starting later in pregnancy and no pattern to suggest a common cause; however, potential limitations of registries should be recognized. Providers are strongly encouraged to report eligible patients.

Key Contacts Website: www.APRegistry.com Email: SM_APR@APRegistry.com The Antiretroviral Pregnancy Registry 301 Government Center Drive Wilmington, NC 28403 US, Canada (toll-free): (800) 258-4263 (Telephone)   (800) 800-1052 (Fax) International: +1-910-256-0637 (Fax) UK, Germany, France (toll-free): (00800) 5913-1359 (Telephone) (00800) 5812-1658 (Fax) EUROPE: +32-2-714-5028 (Telephone) +32-2-714-5024 (Fax) BRAZIL (toll-free): (0800) 892-1472 (Fax)

Acknowledgements The authors acknowledge the outstanding efforts of all the clinicians submitting cases to the APR, as well as the valuable contributions of the APR Steering Committee and the Syneos Health, Coordinating Center Staff. Independent Advisory Committee Members: Cynthia Holcroft-Argani, MD, Johns Hopkins Medical Center; Karen Beckerman, MD, Carl Icahn School of Medicine at Mt Sinai; Nahida Chakhtoura, MD, National Institutes of Health; Kenneth Dominguez, MD, MPH, Centers for Disease Control & Prevention; Kathryn Arnold, MD, National Center on Birth Defects and Developmental Disabilities; Lynne Mofenson, MD, Elizabeth Glaser Pediatric AIDS Foundation; Andreas Pikis, MD, Food and Drug Administration; Rosemary Ramroop, Johns Hopkins University; Nancy Santanello, MD, MS, FISPE, Independent Pharmacoepidemiologist; William Short, MD, MPH, AAHIVS, The University of Pennsylvania; Claire Thorne, PhD, Institute of Child Health, University College London; Heather Watts, MD, Office of the Global AIDS Coordinator & Health Diplomacy, U.S. Dept. of State